Sunday 8 November 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
3
Average plausibility
87%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
01HealthSouth America

Pope Leo visits Uruguay three weeks after lung cancer surgery

Several outlets report the pope’s arrival and three-country itinerary, but his recovery and the reported Mass attendance need more careful qualification.

AP and OSV News report that Pope Leo XIV arrived in Uruguay on November 6, roughly three weeks after lung cancer surgery. France 24 describes a 12-day tour covering Uruguay, Argentina and Peru, while DW reports that more than 40,000 people gathered for his first Mass of the trip. Reports describe Leo as feeling well, but his own remarks and medical statements quoted by news outlets do not establish that he has fully recovered.

What holds up

  • ✓AP and OSV News both report Leo’s arrival in Montevideo, and France 24’s next-day coverage places him in Uruguay. AP, France 24 and CNN agree on a 12-day trip, with France 24 and CNN naming the same three countries.
  • ✓The reports consistently place lung cancer surgery about three weeks before the visit. CNN adds medical context: it quotes his surgeon saying there were no clinical reasons to cancel the trip, although that is not a guarantee against complications.

What doesn't yet

  • ?DW alone supplies the attendance figure of more than 40,000 in the evidence used here. Its excerpt does not identify who counted the crowd or how.
  • ?BBC’s short item leaves “pretty good health” unattributed; AP and OSV News attribute similar upbeat assessments to Leo himself. These are excerpts, not full-article verification, and repeated coverage is not always fresh reporting: The Journal reproduces AP’s account rather than providing a separate confirmation.

Ask before you share

  • →Has the Vatican or his medical team published a current recovery update, rather than just clearance given before departure?
  • →Who estimated the Mass attendance, and does the figure count people present or expected visitors?

Sources & original reporting

  1. [1]BBC News · Published 7 Nov 2026 · bbc.co.uk
  2. [2]Associated Press · Published 7 Nov 2026 · apnews.com
  3. [3]France 24 · Published 7 Nov 2026 · france24.com
  4. [4]DW · Published 7 Nov 2026 · dw.com
  5. [5]CNN · Published 6 Nov 2026 · us.cnn.com
  6. [6]The Journal · Published 6 Nov 2026 · the-journal.com
  7. [7]Osvnews · Published 7 Nov 2026 · osvnews.com
02HealthAsia-Pacific

Magnitude 5.7 earthquake injures dozens in central Japan, CNA reports

Reports support CNA’s account of a damaging earthquake, but injury totals vary and Japan’s preliminary magnitude of 5.7 differs from the US estimate.

CNA reports that a magnitude 5.7 earthquake injured dozens in central Japan. AFP and Kyodo coverage places the quake in Shizuoka Prefecture at 1:04 a.m. on November 8. AP reports at least 22 injuries and says Japan’s Meteorological Agency measured magnitude 5.7, while the US Geological Survey measured 5.5. Reports also describe broken shop windows and train disruptions, with no tsunami warning issued.

What holds up

  • ✓NHK, AP, AFP and Kyodo coverage supports the earthquake’s location and Japan’s reported magnitude of 5.7. Their magnitude accounts largely draw on the same Japanese agency, rather than separate measurements.
  • ✓The reports consistently describe injuries: Kyodo cites authorities reporting at least 20 in Aichi Prefecture, while AP cites local media reporting at least 22. AFP also reports injuries, broken windows and train disruptions.
  • ✓NHK reports no tsunami threat, and AFP reports that no tsunami warning was issued. That supports a limited statement about tsunami risk, not an absence of other damage.

What doesn't yet

  • ?Magnitude 5.7 is Japan’s preliminary estimate, not an agreed measurement across agencies: AP reports a US Geological Survey estimate of 5.5.
  • ?The injury count remains unsettled. UA News, citing CNA and local media, gives at least 24; AP gives at least 22; Kyodo gives at least 20 specifically in Aichi. Different geographic coverage or reporting times could explain the totals, but the excerpts do not establish that.
  • ?Many websites repeat wire coverage rather than add new reporting: WRIC carries AP, Nampa carries AFP, and Bernama carries Kyodo. These snippets and excerpts do not provide full-article verification or direct access to the agencies’ records.

Ask before you share

  • →Have local authorities released an updated injury total covering all affected prefectures, including how many injuries are serious?
  • →Have Japan’s Meteorological Agency or the US Geological Survey revised their magnitude estimates?
  • →Which train services remain disrupted, and what damage have authorities confirmed beyond the initial reports?

Sources & original reporting

  1. [1]CNA · Published 8 Nov 2026 · channelnewsasia.com
  2. [2]Ua · Published 8 Nov 2026 · ua.news
  3. [3]Bernama · Published 8 Nov 2026 · bernama.com
  4. [4]Wric · Published 8 Nov 2026 · wric.com
  5. [5]Nampa · Published 8 Nov 2026 · nampa.org
  6. [6]Www3 Nhk · Published 7 Nov 2026 · www3.nhk.or.jp
03HealthGlobal

Ebola research highlights vaccine gap for Bundibugyo strain

Recent reports support the lack of a licensed Bundibugyo vaccine, but promising research has not yet established protection against the virus.

DW reports that Bundibugyo Ebola is causing a current outbreak and that new research raises hopes for broader vaccine protection. A recent MSF brief places the outbreak response in the Democratic Republic of the Congo and says no vaccine is licensed specifically for Bundibugyo. MSF says researchers are testing existing Ebola vaccines and new candidates, but protection from Ervebo against Bundibugyo remains unproven.

What holds up

  • ✓DW and MSF both describe a current Bundibugyo outbreak. MSF's recent brief also supports the central vaccine gap, with the more precise wording that no vaccine is licensed specifically for Bundibugyo.
  • ✓Research is underway, rather than merely proposed: MSF names the BRAVO study and Tumaini trial. As background, a July ANRS account reports that samples from people vaccinated against Zaire Ebola contained antibodies against Bundibugyo, while explicitly warning that this does not demonstrate clinical protection.

What doesn't yet

  • ?DW's wording that there is “no vaccine” is too broad without qualification. Candidates exist, and MSF says the DRC is using Ervebo, but its effectiveness against Bundibugyo remains unproven.
  • ?The supplied DW excerpt does not identify the research behind its optimism or provide methods or results. The older antibody findings offer a reason to investigate, not evidence that a vaccine protects people against several Ebola types.
  • ?Only a few outside newsrooms are represented in the evidence used here, so other accounts may be missing. ReliefWeb repeats the MSF brief rather than providing a separate reporting check; MSF also leads one of the studies. These excerpts are not full-article verification.

Ask before you share

  • →Which study does DW mean, and did it measure antibodies, illness prevention, or another outcome?
  • →Have trials shown that Ervebo or a Bundibugyo-specific candidate prevents disease, and what safety and effectiveness results are available?
  • →Does “no vaccine” mean no licensed Bundibugyo vaccine, rather than no experimental options or vaccines being tested for protection?

Sources & original reporting

  1. [1]DW · Published 7 Nov 2026 · dw.com
  2. [2]Reliefweb · Published 2 Nov 2026 · reliefweb.int
  3. [3]Msfaccess · Published 27 Oct 2026 · msfaccess.org
  4. [4]Anrs · Published 24 Jul 2026 · anrs.fr